These findings suggest that ANLN can be an indicator of the malignant phenotype, disease prognosis, immune infiltration, and PD-L1 expression, which provides a rationale for its use in predicting the responses of patients with BLCA to anti-PD-L1 drugs. The gene discussed is ANLN; the disease is bladder transitional cell carcinoma.